Diagnosis of uncertain primary tumors with the Pathwork^® tissue-of-origin test

References

• Oien KA. Pathologic evaluation of unknown primary cancer. Semin. Oncol.36(1), 8–37 (2009).
   PubMed Web of Science ®Google Scholar
• Pavlidis N, Fizazi K. Carcinoma of unknown primary (CUP). Crit. Rev. Oncol. Hematol.69(3), 271–278 (2009).
   PubMed Web of Science ®Google Scholar
• Bahrami A, Truong LD, Ro JY. Undifferentiated tumor: true identity by immunohistochemistry. Arch. Pathol. Lab. Med.132(3), 326–348 (2008).
   PubMed Web of Science ®Google Scholar
• Varadhachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer100(9), 1776–1785 (2004).
   PubMed Web of Science ®Google Scholar
• Schapira DV, Jarrett AR. The need to consider survival, outcome, and expense when evaluating and treating patients with unknown primary carcinoma. Arch. Intern. Med.155(19), 2050–2054 (1995).
   PubMedGoogle Scholar
• Pavlidis N, Fizazi K. Cancer of unknown primary (CUP). Crit. Rev. Oncol. Hematol.54(3), 243–250 (2005).
   PubMed Web of Science ®Google Scholar
• van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW, Hillen HF. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984–1992. Eur. J. Cancer38(3), 409–413 (2002).
   Google Scholar
• Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J. Clin. Oncol.13(8), 2094–2103 (1995).
   PubMed Web of Science ®Google Scholar
• Greco FA, Pavlidis N. Treatment for patients with unknown primary carcinoma and unfavorable prognostic factors. Semin. Oncol.36(1), 65–74 (2009).
   Google Scholar
• Hainsworth JD, Fizazi K. Treatment for patients with unknown primary cancer and favorable prognostic factors. Semin. Oncol.36(1), 44–51 (2009).
   PubMed Web of Science ®Google Scholar
• Winn RJ, McClure JS. Occult Primary. V.I.2009. In: NCCN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network, GA, USA (2009).
   Google Scholar
• Bishop JF, Tracey E, Glass P, Jelfs P, Roder D. Prognosis of sub-types of cancer of unknown primary (CUP) compared to metastatic cancer. J. Clin. Oncol.25(Suppl. 18), 21010 (2007).
   Google Scholar
• Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science270(5235), 467–470 (1995).
   PubMed Web of Science ®Google Scholar
• Golub TR, Slonim DK, Tamayo P et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science286(5439), 531–537 (1999).
   PubMed Web of Science ®Google Scholar
• Su AI, Welsh JB, Sapinoso LM et al. Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res.61(20), 7388–7393 (2001).
   PubMed Web of Science ®Google Scholar
• Ramaswamy S, Tamayo P, Rifkin R et al. Multiclass cancer diagnosis using tumor gene expression signatures. Proc. Natl Acad. Sci. USA98(26), 15149–15154 (2001).
   PubMed Web of Science ®Google Scholar
• Bhattacharjee A, Richards WG, Staunton J et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl Acad. Sci. USA98(24), 13790–13795 (2001).
   PubMed Web of Science ®Google Scholar
• Weigelt B, Glas AM, Wessels LF, Witteveen AT, Peterse JL, van’t Veer LJ. Gene expression profiles of primary breast tumors maintained in distant metastases. Proc. Natl Acad. Sci. USA100(26), 15901–15905 (2003).
   PubMed Web of Science ®Google Scholar
• Bloom G, Yang IV, Boulware D et al. Multi-platform, multi-site, microarray-based human tumor classification. Am. J. Pathol.164(1), 9–16 (2004).
   PubMed Web of Science ®Google Scholar
• Tothill RW, Kowalczyk A, Rischin D et al. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res.65(10), 4031–4040 (2005).
   PubMed Web of Science ®Google Scholar
• Tan PK, Downey TJ, Spitznagel EL Jr et al. Evaluation of gene expression measurements from commercial microarray platforms. Nucleic Acids Res.31(19), 5676–5684 (2003).
   PubMed Web of Science ®Google Scholar
• Johnson K, Lin S. QA/QC as a pressing need for microarray analysis: meeting report from CAMDA’02. BioTechniques (Suppl.), 62–63 (2003).
   Google Scholar
• Ma C, Lyons-Weiler M, Liang W et al.In vitro transcription amplification and labeling methods contribute to the variability of gene expression profiling with DNA microarrays. J. Mol. Diagn.8(2), 183–192 (2006).
   Google Scholar
• Larkin JE, Frank BC, Gavras H, Sultana R, Quackenbush J. Independence and reproducibility across microarray platforms. Nat. Methods2(5), 337 (2005).
   PubMed Web of Science ®Google Scholar
• Bammler T, Beyer RP, Bhattacharya S et al. Members of the toxicogenomics research consortium. standardizing global gene expression analysis between laboratories and across platforms. Nat. Methods2(5), 351 (2005).
   PubMed Web of Science ®Google Scholar
• Dobbin KK, Beer DG, Meyerson M et al. Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin. Cancer Res.11(2 Pt 1), 565–572 (2005).
   PubMed Web of Science ®Google Scholar
• Irizarry RA, Warren D, Spencer F et al. Multiple-laboratory comparison of microarray platforms. Nat. Methods2(5), 345 (2005).
   PubMed Web of Science ®Google Scholar
• Moraleda J, Grove N, Tran Q et al. Gene expression data analytics with interlaboratory validation for identifying anatomical sites of origin of metastatic carcinomas. J. Clin. Oncol.22(Suppl. 14), 9625 (2004).
   Google Scholar
• Dumur CI, Lyons-Weiler M, Sciulli C et al. Interlaboratory performance of a microarray-based gene expression test to determine tissue of origin in poorly differentiated and undifferentiated cancers. J. Mol. Diagn.10(1), 67–77 (2008).
   PubMed Web of Science ®Google Scholar
• Monzon FA, Lyons-Weiler M, Buturovic LJ et al. Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. J. Clin. Oncol.27(15), 2503–2508 (2009).
   PubMed Web of Science ®Google Scholar
• Ma XJ, Patel R, Wang X et al. Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay. Arch. Pathol. Lab. Med.130(4), 465–473 (2006).
   PubMed Web of Science ®Google Scholar
• Glas A, Floore A, Delahaye L et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics7(1), 278 (2006).
   PubMed Web of Science ®Google Scholar
• Bridgewater J, van Laar R, Floore A, Van TVL. Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary. Br. J. Cancer98(8), 1425–1430 (2008).
   PubMed Web of Science ®Google Scholar
• Rosenfeld N, Aharonov R, Meiri E et al. MicroRNAs accurately identify cancer tissue origin. Nat. Biotechnol.26(4), 462–469 (2008).
   PubMed Web of Science ®Google Scholar
• Simon R. Roadmap for developing and validating therapeutically relevant genomic classifiers. J. Clin. Oncol.23(29), 7332–7341 (2005).
   PubMed Web of Science ®Google Scholar
• Simon R, Radmacher MD, Dobbin K, McShane LM. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J. Natl Cancer Inst.95(1), 14–18 (2003).
   PubMed Web of Science ®Google Scholar
• Jennings L, Van Deerlin VM, Gulley ML. Recommended principles and practices for validating clinical molecular pathology tests. Arch. Pathol. Lab. Med.133(5), 743–755 (2009).
   PubMed Web of Science ®Google Scholar
• Levi F, Te VC, Erler G, Randimbison L, La Vecchia C. Epidemiology of unknown primary tumours. Eur. J. Cancer38(13), 1810–1812 (2002).
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J. Clin.59(4), 225–249 (2009).
   PubMed Web of Science ®Google Scholar
• Pillai R, Deeter R, Rigl CT, Halks-Miller M, Henner WD, Buturovic L. Validation of a microarray-based gene expression test for tumors with uncertain origins using formalin-fixed paraffin-embedded (FFPE) specimens. J. Clin. Oncol.27(Suppl. 15), e22015 (2009).
   Google Scholar
• Werner M, Chott A, Fabiano A, Battifora H. Effect of formalin tissue fixation and processing on immunohistochemistry. Am. J. Surg. Pathol.24(7), 1016–1019 (2000).
   PubMed Web of Science ®Google Scholar
• Masuda N, Ohnishi T, Kawamoto S, Monden M, Okubo K. Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples. Nucleic Acids Res.27(22), 4436–4443 (1999).
   PubMed Web of Science ®Google Scholar
• Pentheroudakis G, Greco FA, Pavlidis N. Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review. Cancer Treat Rev.35(3), 221–227 (2009).
   PubMed Web of Science ®Google Scholar
• Greco FA, Spigel DR, Yardley DA et al. Unknown primary cancer (UPC): accuracy of tissue of origin prediction by molecular profiling. J. Clin. Oncol.27(Suppl. 15), 11070 (2009).
   Google Scholar
• Dennis JL, Hvidsten TR, Wit EC et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin. Cancer Res.11(10), 3766–3772 (2005).
   PubMed Web of Science ®Google Scholar
• Horlings HM, van Laar RK, Kerst JM et al. Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J. Clin. Oncol.26(27), 4435–4441 (2008).
   PubMed Web of Science ®Google Scholar
• Varadhachary GR, Talantov D, Raber MN et al. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J. Clin. Oncol.26(27), 4442–4448 (2008).
   PubMed Web of Science ®Google Scholar
• Varadhachary GR, Raber MN, Matamoros A, Abbruzzese JL. Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions. Lancet Oncol.9(6), 596–599 (2008).
   PubMed Web of Science ®Google Scholar